Michael Barbella, Managing Editor12.13.23
Sonex Health is marking a significant milestone in carpal tunnel treatment, noting that more than 20,000 patients have now been treated for carpal tunnel release (CTR) using UltraGuideCTR and real-time ultrasound guidance.
This milestone follows a $40 million Series B financing round, the proceeds of which will be used to expand access to the company's commercially available devices that use ultrasound guidance to safely and effectively treat patients suffering from carpal tunnel syndrome (CTS) and trigger finger (TF). UltraGuideCTR and real-time ultrasound guidance improves the visualization of all wrist and hand critical anatomy, enabling surgeons to better identify the safe zone and create space to transect the TCL while protecting sensitive anatomic structures.
UltraGuideCTR features include a low profile tapered tip that allows the device to be inserted through a small incision, Stealth MicroGuard balloons that gently create space and protect critical anatomy in the carpal tunnel prior to and during transection, and Meerkat Technology. UltraGuideCTR's TCL Blade is hidden in the tip of the device for safe insertion and removal and cannot be activated unless the Stealth MicroGuard balloons are inflated.
Surgeons insert UltraGuideCTR through a small incision over the proximal carpal tunnel region. Meerkat Technology coordinates the TCL Blade's activation and Stealth MicroGuards inflation; once in position and the Stealth MicroGuards deployed, the TCL Blade is advanced from the device tip to transect, or divide, the transverse carpal ligament. Throughout the procedure, the transverse carpal ligament and relevant anatomic structures are visualized directly, in real-time, with ultrasound imaging.
Sonex Health, Inc. develops ultrasound-guided therapies to treat common orthopedic conditions affecting the extremities, including entrapment neuropathies and tendinopathies. The company’s proprietary devices allow surgeons to use real-time ultrasound guidance to visualize critical anatomy throughout procedures, thereby reducing both invasiveness and the cost of care. UltraGuideCTR received U.S. Food and Drug Administration clearance in 2019 and UltraGuideTFR—designed to treat trigger finger (a.k.a., stenosing tenosynovitis), was released last year.
Founded in 2018 to support the Sonex Health mission and clinical excellence, the Institute of Advanced Ultrasound Guided Procedures is focused on innovation supported by robust clinical research and professional education and training that transforms the treatment experience for patients, providers, and payers.
This milestone follows a $40 million Series B financing round, the proceeds of which will be used to expand access to the company's commercially available devices that use ultrasound guidance to safely and effectively treat patients suffering from carpal tunnel syndrome (CTS) and trigger finger (TF). UltraGuideCTR and real-time ultrasound guidance improves the visualization of all wrist and hand critical anatomy, enabling surgeons to better identify the safe zone and create space to transect the TCL while protecting sensitive anatomic structures.
UltraGuideCTR features include a low profile tapered tip that allows the device to be inserted through a small incision, Stealth MicroGuard balloons that gently create space and protect critical anatomy in the carpal tunnel prior to and during transection, and Meerkat Technology. UltraGuideCTR's TCL Blade is hidden in the tip of the device for safe insertion and removal and cannot be activated unless the Stealth MicroGuard balloons are inflated.
Surgeons insert UltraGuideCTR through a small incision over the proximal carpal tunnel region. Meerkat Technology coordinates the TCL Blade's activation and Stealth MicroGuards inflation; once in position and the Stealth MicroGuards deployed, the TCL Blade is advanced from the device tip to transect, or divide, the transverse carpal ligament. Throughout the procedure, the transverse carpal ligament and relevant anatomic structures are visualized directly, in real-time, with ultrasound imaging.
Sonex Health, Inc. develops ultrasound-guided therapies to treat common orthopedic conditions affecting the extremities, including entrapment neuropathies and tendinopathies. The company’s proprietary devices allow surgeons to use real-time ultrasound guidance to visualize critical anatomy throughout procedures, thereby reducing both invasiveness and the cost of care. UltraGuideCTR received U.S. Food and Drug Administration clearance in 2019 and UltraGuideTFR—designed to treat trigger finger (a.k.a., stenosing tenosynovitis), was released last year.
Founded in 2018 to support the Sonex Health mission and clinical excellence, the Institute of Advanced Ultrasound Guided Procedures is focused on innovation supported by robust clinical research and professional education and training that transforms the treatment experience for patients, providers, and payers.